TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07158775: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Sponsor: Bionic Sight LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07158775 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07158775 Rescue Dossier →